Y K Hamied
- All
- News
- Videos
-
Drug Firms Facing Challenging Times Due To Price Control: Cipla
Drug companies are facing a tough environment due to the government bringing more products under the price control policy as also tightening of registration procedure that has impacted time to market newer products, Cipla chairman Y K Hamied has said.
-
Y K Hamied Increases Stake in Cipla to Over 20%
In a move aimed at realignment of family shareholding, Cipla patriarch Y K Hamied has increased his stake in the homegrown drug major to over 20 per cent by acquiring additional 5 per cent.
-
Y K Hamied to Increase Stake in Cipla to Over 20%
In a move aimed at realignment of family shareholding, Cipla patriarch Y K Hamied plans to increase his holding to over 20 per cent by acquiring an over 5 per cent additional stake in the homegrown drug major.
-
Cipla shares fall 5.1% on poor Q3 profits
The street was concerned about operating profit margins at 20 per cent that fell below street expectation of over 22 per ccent.
-
Drug Firms Facing Challenging Times Due To Price Control: Cipla
Drug companies are facing a tough environment due to the government bringing more products under the price control policy as also tightening of registration procedure that has impacted time to market newer products, Cipla chairman Y K Hamied has said.
-
Y K Hamied Increases Stake in Cipla to Over 20%
In a move aimed at realignment of family shareholding, Cipla patriarch Y K Hamied has increased his stake in the homegrown drug major to over 20 per cent by acquiring additional 5 per cent.
-
Y K Hamied to Increase Stake in Cipla to Over 20%
In a move aimed at realignment of family shareholding, Cipla patriarch Y K Hamied plans to increase his holding to over 20 per cent by acquiring an over 5 per cent additional stake in the homegrown drug major.
-
Cipla shares fall 5.1% on poor Q3 profits
The street was concerned about operating profit margins at 20 per cent that fell below street expectation of over 22 per ccent.
